Advisory Committee on Immunization Practices, 45905 [2023-15190]
Download as PDF
Federal Register / Vol. 88, No. 136 / Tuesday, July 18, 2023 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2023–0063]
Advisory Committee on Immunization
Practices
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice and request for comment.
AGENCY:
In accordance with regulatory
provisions, the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
Advisory Committee on Immunization
Practices (ACIP). This meeting is open
to the public. Time will be available for
public comment.
DATES: The meeting will be held on
August 3, 2023, 11 a.m. to 3:30 p.m.,
EDT (date and times subject to change;
see the ACIP website for updates:
https://www.cdc.gov/vaccines/acip/
index.htm).
Written comments will be received
July 19, 2023–August 2, 2023.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2023–
0063, by either of the methods listed
below. CDC does not accept comments
by email.
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: Ms. Stephanie Thomas, ACIP
Meeting, Centers for Disease Control
and Prevention, 1600 Clifton Road NE,
Mailstop H24–8, Atlanta, Georgia
30329–4027. Attn: Docket No. CDC–
2023–0063.
Instructions: All submissions received
must include the Agency name and
docket number. All relevant comments
received in conformance with the
https://www.regulations.gov suitability
policy will be posted without change to
https://www.regulations.gov, including
any personal information provided. For
access to the docket to read background
documents or comments received, go to
https://www.regulations.gov.
The meeting will be webcast live via
the World Wide Web. The webcast link
can be found on the ACIP website at
https://www.cdc.gov/vaccines/acip/
index.html.
ddrumheller on DSK120RN23PROD with NOTICES1
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Stephanie Thomas, Committee
Management Specialist, Advisory
Committee on Immunization Practices,
National Center for Immunization and
Respiratory Diseases, Centers for
Disease Control and Prevention, 1600
VerDate Sep<11>2014
19:16 Jul 17, 2023
Jkt 259001
Clifton Road NE, Mailstop H24–8,
Atlanta, Georgia 30329–4027.
Telephone: (404) 639–8836; Email:
ACIP@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee on
Immunization Practices (ACIP) is
charged with advising the Director,
Centers for Disease Control and
Prevention (CDC), on the use of
immunizing agents. In addition, under
42 U.S.C. 1396s, the Committee is
mandated to establish and periodically
review and, as appropriate, revise the
list of vaccines for administration to
vaccine-eligible children through the
Vaccines For Children program, along
with schedules regarding dosing
interval, dosage, and contraindications
to administration of vaccines. Further,
under applicable provisions of the
Affordable Care Act and section 2713 of
the Public Health Service Act,
immunization recommendations of
ACIP that have been approved by the
Director, CDC, and appear on CDC
immunization schedules generally must
be covered by applicable health plans.
Matters to be Considered: The agenda
will include discussion of nirsevimab
for prevention of respiratory syncytial
virus (RSV). A recommendation vote
and a Vaccines for Children vote are
scheduled. Agenda items are subject to
change as priorities dictate. For more
information on the meeting agenda, visit
https://www.cdc.gov/vaccines/acip/
meetings/.
Meeting Information: The meeting
will be webcast live via the World Wide
Web. For more information on ACIP,
please visit the ACIP website: https://
www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations
are invited to participate by submitting
written views, recommendations, and
data. Please note that comments
received, including attachments and
other supporting materials, are part of
the public record and are subject to
public disclosure. Comments will be
posted on https://www.regulations.gov.
Therefore, do not include any
information in your comment or
supporting materials that you consider
confidential or inappropriate for public
disclosure. If you include your name,
contact information, or other
information that identifies you in the
body of your comments, that
information will be on public display.
CDC will review all submissions and
may choose to redact, or withhold,
submissions containing private or
proprietary information such as Social
Security numbers, medical information,
inappropriate language, or duplicate/
PO 00000
Frm 00024
Fmt 4703
Sfmt 9990
45905
near-duplicate examples of a mass-mail
campaign. CDC will carefully consider
all comments submitted into the docket.
Written Public Comment: The docket
will be opened to receive written
comments on July 19, 2023. Written
comments must be received August 2,
2023.
Oral Public Comment: This meeting
will include time for members of the
public to make an oral comment.
Priority will be given to individuals
who submit a request to make an oral
public comment before the meeting
according to the procedures below.
Procedure for Oral Public Comment:
All persons interested in making an oral
public comment at the August 3, 2023,
ACIP meeting must submit a request at
https://www.cdc.gov/vaccines/acip/
meetings/ no later than 11:59
p.m., EDT, August 1, 2023, according to
the instructions provided.
If the number of persons requesting to
speak is greater than can be reasonably
accommodated during the scheduled
time, CDC will conduct a lottery to
determine the speakers for the
scheduled public comment session.
CDC staff will notify individuals
regarding their request to speak by email
on August 2, 2023. To accommodate the
significant interest in participation in
the oral public comment session of
ACIP meetings, each speaker will be
limited to three minutes, and each
speaker may only speak once per
meeting.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
[FR Doc. 2023–15190 Filed 7–17–23; 8:45 am]
BILLING CODE 4163–18–P
E:\FR\FM\18JYN1.SGM
18JYN1
Agencies
[Federal Register Volume 88, Number 136 (Tuesday, July 18, 2023)]
[Notices]
[Page 45905]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-15190]
[[Page 45905]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[Docket No. CDC-2023-0063]
Advisory Committee on Immunization Practices
AGENCY: Centers for Disease Control and Prevention (CDC), Department of
Health and Human Services (HHS).
ACTION: Notice and request for comment.
-----------------------------------------------------------------------
SUMMARY: In accordance with regulatory provisions, the Centers for
Disease Control and Prevention (CDC) announces the following meeting of
the Advisory Committee on Immunization Practices (ACIP). This meeting
is open to the public. Time will be available for public comment.
DATES: The meeting will be held on August 3, 2023, 11 a.m. to 3:30
p.m., EDT (date and times subject to change; see the ACIP website for
updates: https://www.cdc.gov/vaccines/acip/index.htm).
Written comments will be received July 19, 2023-August 2, 2023.
ADDRESSES: You may submit comments, identified by Docket No. CDC-2023-
0063, by either of the methods listed below. CDC does not accept
comments by email.
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments.
Mail: Ms. Stephanie Thomas, ACIP Meeting, Centers for
Disease Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8,
Atlanta, Georgia 30329-4027. Attn: Docket No. CDC-2023-0063.
Instructions: All submissions received must include the Agency name
and docket number. All relevant comments received in conformance with
the https://www.regulations.gov suitability policy will be posted
without change to https://www.regulations.gov, including any personal
information provided. For access to the docket to read background
documents or comments received, go to https://www.regulations.gov.
The meeting will be webcast live via the World Wide Web. The
webcast link can be found on the ACIP website at https://www.cdc.gov/vaccines/acip/.
FOR FURTHER INFORMATION CONTACT: Stephanie Thomas, Committee Management
Specialist, Advisory Committee on Immunization Practices, National
Center for Immunization and Respiratory Diseases, Centers for Disease
Control and Prevention, 1600 Clifton Road NE, Mailstop H24-8, Atlanta,
Georgia 30329-4027. Telephone: (404) 639-8836; Email: [email protected].
SUPPLEMENTARY INFORMATION:
Purpose: The Advisory Committee on Immunization Practices (ACIP) is
charged with advising the Director, Centers for Disease Control and
Prevention (CDC), on the use of immunizing agents. In addition, under
42 U.S.C. 1396s, the Committee is mandated to establish and
periodically review and, as appropriate, revise the list of vaccines
for administration to vaccine-eligible children through the Vaccines
For Children program, along with schedules regarding dosing interval,
dosage, and contraindications to administration of vaccines. Further,
under applicable provisions of the Affordable Care Act and section 2713
of the Public Health Service Act, immunization recommendations of ACIP
that have been approved by the Director, CDC, and appear on CDC
immunization schedules generally must be covered by applicable health
plans.
Matters to be Considered: The agenda will include discussion of
nirsevimab for prevention of respiratory syncytial virus (RSV). A
recommendation vote and a Vaccines for Children vote are scheduled.
Agenda items are subject to change as priorities dictate. For more
information on the meeting agenda, visit https://www.cdc.gov/vaccines/acip/meetings/.
Meeting Information: The meeting will be webcast live via the World
Wide Web. For more information on ACIP, please visit the ACIP website:
https://www.cdc.gov/vaccines/acip/.
Public Participation
Interested persons or organizations are invited to participate by
submitting written views, recommendations, and data. Please note that
comments received, including attachments and other supporting
materials, are part of the public record and are subject to public
disclosure. Comments will be posted on https://www.regulations.gov.
Therefore, do not include any information in your comment or supporting
materials that you consider confidential or inappropriate for public
disclosure. If you include your name, contact information, or other
information that identifies you in the body of your comments, that
information will be on public display. CDC will review all submissions
and may choose to redact, or withhold, submissions containing private
or proprietary information such as Social Security numbers, medical
information, inappropriate language, or duplicate/near-duplicate
examples of a mass-mail campaign. CDC will carefully consider all
comments submitted into the docket.
Written Public Comment: The docket will be opened to receive
written comments on July 19, 2023. Written comments must be received
August 2, 2023.
Oral Public Comment: This meeting will include time for members of
the public to make an oral comment. Priority will be given to
individuals who submit a request to make an oral public comment before
the meeting according to the procedures below.
Procedure for Oral Public Comment: All persons interested in making
an oral public comment at the August 3, 2023, ACIP meeting must submit
a request at https://www.cdc.gov/vaccines/acip/meetings/ no
later than 11:59 p.m., EDT, August 1, 2023, according to the
instructions provided.
If the number of persons requesting to speak is greater than can be
reasonably accommodated during the scheduled time, CDC will conduct a
lottery to determine the speakers for the scheduled public comment
session. CDC staff will notify individuals regarding their request to
speak by email on August 2, 2023. To accommodate the significant
interest in participation in the oral public comment session of ACIP
meetings, each speaker will be limited to three minutes, and each
speaker may only speak once per meeting.
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2023-15190 Filed 7-17-23; 8:45 am]
BILLING CODE 4163-18-P